{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:44:57Z","timestamp":1792637097489,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40262-020-00953-4","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T21:02:20Z","timestamp":1604091740000},"page":"501-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression"],"prefix":"10.1007","volume":"60","clinical-trial-number":[{"clinical-trial-number":"nct01780259","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01980303","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02129088","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02846519","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02343289","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02568176","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02345148","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02682225","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01998958","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02133001","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02417064","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02418585","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02422186","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Carlos","family":"Perez-Ruixo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"Rossenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zannikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskaran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Perez-Ruixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"953_CR1","unstructured":"WHO. WHO fact sheet on depression 2018. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. Accessed 19 Feb 2020."},{"issue":"4","key":"953_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334\u201341.","journal-title":"JAMA Psychiatry"},{"key":"953_CR3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4088\/JCP.v69n0610","volume":"69","author":"R Machado-Vieira","year":"2008","unstructured":"Machado-Vieira R, Salvadore G, Luckenbaugh D, Manji H, Zarate C. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depression. J Clin Psychiatry. 2008;69:946\u201358.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 8","key":"953_CR4","first-page":"17","volume":"68","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(Suppl. 8):17\u201325.","journal-title":"J Clin Psychiatry"},{"key":"953_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/87865","volume":"7","author":"H Manji","year":"2001","unstructured":"Manji H, Drevets W, Charney D. The cellular neurobiology of depression. Nat Med. 2001;7:541\u20137.","journal-title":"Nat Med"},{"key":"953_CR6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"J Murrough","year":"2017","unstructured":"Murrough J, Abdallah C, Mathew S. Targeting glutamate signaling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"953_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"R Duman","year":"2016","unstructured":"Duman R, Aghajanian G, Sanacora G, Krystal J. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238\u201349.","journal-title":"Nat Med"},{"key":"953_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-019-01084-z","author":"U Kaur","year":"2019","unstructured":"Kaur U, Pathak BK, Singh A, et al. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci. 2019. https:\/\/doi.org\/10.1007\/s00406-019-01084-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"2","key":"953_CR9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139\u201348.","journal-title":"JAMA Psychiatry"},{"key":"953_CR10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"S Montgomery","year":"1979","unstructured":"Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"953_CR11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"953_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris P, Riggs L, Highland J, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"953_CR13","unstructured":"Spravato: US label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211243lbl.pdf. Accessed 19 Feb 2020."},{"key":"953_CR14","unstructured":"Spravato: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf. Accessed 19 Feb 2020."},{"key":"953_CR15","first-page":"887","volume":"29","author":"Y Yanagihara","year":"2001","unstructured":"Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001;29:887\u201390.","journal-title":"Drug Metab Dispos"},{"key":"953_CR16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1742-7843.2012.00908.x","volume":"111","author":"MA Peltoniemi","year":"2012","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, et al. Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin Pharmacol Toxicol. 2012;111:325\u201332.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"953_CR17","unstructured":"Janssen Research and Development. A study to assess the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in healthy participants [ClinicalTrials.gov Identifier: NCT01780259]. US National Institutes of Health, Clinicaltrials.gov. 2013. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01780259. Accessed 11 Oct 2020."},{"key":"953_CR18","unstructured":"Janssen Research and Development. A study to assess the pharmacokinetics of intranasally administered esketamine in healthy japanese and caucasian volunteers [ClinicalTrials.gov Identifier: NCT01980303]. US National Institutes of Health, Clinicaltrials.gov. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01980303. Accessed 11 Oct 2020."},{"key":"953_CR19","unstructured":"Janssen Research and Development. A pharmacokinetic, safety and tolerability study of esketamine in healthy elderly and adult participants [ClinicalTrials.gov Identifier: NCT02129088]. US National Institutes of Health, Clinicaltrials.gov. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02129088. Accessed 11 Oct 2020."},{"key":"953_CR20","unstructured":"Janssen Research and Development. Pharmacokinetic, safety, and tolerability study of intranasally administered esketamine in healthy Han Chinese, Korean, Japanese, and Caucasian participants and the effects of rifampin on the pharmacokinetics of intranasally administered esketamine. [ClinicalTrials.gov Identifier: NCT02846519]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02846519. Accessed 11 Oct 2020."},{"key":"953_CR21","unstructured":"Janssen Research and Development. A study to evaluate the absolute bioavailability of intranasal and oral esketamine and the effects of clarithromycin on the pharmacokinetics of intranasal esketamine in healthy participants [ClinicalTrials.gov Identifier: NCT02343289]. US National Institutes of Health, Clinicaltrials.gov. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02343289. Accessed 11 Oct 2020."},{"key":"953_CR22","unstructured":"Janssen Research and Development. Pharmacokinetic study of intranasal esketamine and its effects on the pharmacokinetics of orally-administered midazolam and bupropion in healthy participants. [ClinicalTrials.gov Identifier: NCT02568176]. US National Institutes of Health, Clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02568176. Accessed 11 Oct 2020."},{"key":"953_CR23","unstructured":"Janssen Research and Development. Pharmacokinetic, safety, and tolerability study of intranasally administered esketamine in elderly and healthy younger adult participants. [ClinicalTrials.gov Identifier: NCT02345148]. US National Institutes of Health, Clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02345148. Accessed 11 Oct 2020."},{"key":"953_CR24","unstructured":"Janssen Research and Development. Crossover study to evaluate the abuse potential of intranasal esketamine compared to racemic intravenous ketamine in nondependent, recreational drug users [ClinicalTrials.gov Identifier: NCT02682225]. US National Institutes of Health, Clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02682225. Accessed 11 Oct 2020."},{"key":"953_CR25","unstructured":"Janssen Research and Development. A study to evaluate the safety and efficacy of intranasal esketamine in treatment-resistant depression (SYNAPSE) [ClinicalTrials.gov Identifier: NCT01998958]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01998958. Accessed 11 Oct 2020."},{"key":"953_CR26","unstructured":"Janssen Research and Development. A double-blind study to assess the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in participants who are assessed to be at imminent risk for suicide [ClinicalTrials.gov Identifier: NCT02133001]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133001. Accessed 11 Oct 2020."},{"key":"953_CR27","unstructured":"Janssen Research and Development. A study to evaluate the efficacy, safety, and tolerability of fixed doses of intranasal esketamine plus an oral antidepressant in adult participants with treatment-resistant depression (TRANSFORM-1) [ClinicalTrials.gov Identifier: NCT02417064]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02417064. Accessed 11 Oct 2020."},{"key":"953_CR28","unstructured":"Janssen Research and Development. A study to evaluate the efficacy, safety, and tolerability of flexible doses of intranasal esketamine plus an oral antidepressant in adult participants with treatment-resistant depression (TRANSFORM-2) [ClinicalTrials.gov Identifier: NCT02418585]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02418585. Accessed 11 Oct 2020."},{"key":"953_CR29","unstructured":"Janssen Research and Development. A study to evaluate the efficacy, safety, and tolerability of intranasal esketamine plus an oral antidepressant in elderly participants with treatment-resistant depression (TRANSFORM-3) [ClinicalTrials.gov Identifier: NCT02422186]. US National Institutes of Health, Clinicaltrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02422186. Accessed 11 Oct 2020."},{"key":"953_CR30","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.1.0 users guides. Ellicott City: Icon Development Solutions; 1989\u20132009."},{"key":"953_CR31","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2012. http:\/\/www.R-project.org\/Guidance for Industry. Accessed 11 Oct 2020."},{"key":"953_CR32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1023\/A:1012065130597","volume":"14","author":"V Piotrovskij","year":"1997","unstructured":"Piotrovskij V, Van Peer A. A model with separate hepato-portal compartment (\u201cfirst-pass\u201d model): fitting to plasma concentration-time profiles in humans. Pharm Res. 1997;14:230\u20137.","journal-title":"Pharm Res"},{"key":"953_CR33","unstructured":"Girard P. Data transformation and parameter transformations in NONMEM. Available from: http:\/\/www.pagemeeting.org\/page\/page2002\/PascalGirardPage2002.pdf. Accessed 19 Feb 2020."},{"issue":"2","key":"953_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacomet Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"953_CR35","first-page":"58","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):58\u201369.","journal-title":"AAPS J"},{"issue":"5","key":"953_CR36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511\u201328.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"953_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA\u2019s statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129\u201333.","journal-title":"Am Stat"},{"key":"953_CR38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41562-017-0189-z","volume":"2","author":"DJ Benjamin","year":"2018","unstructured":"Benjamin DJ, Berger JO, Johnson VE, et al. Redefine statistical significance. Nat Hum Behav. 2018;2:6\u201310.","journal-title":"Nat Hum Behav"},{"issue":"Suppl","key":"953_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond \u201cp < 0.05\u201d. Am Stat. 2019;73(Suppl):1\u201319.","journal-title":"Am Stat."},{"key":"953_CR40","volume-title":"A primer for soft modeling","author":"FR Falk","year":"1992","unstructured":"Falk FR, Miller NB. A primer for soft modeling. Akron: University of Akron Press; 1992."},{"issue":"2","key":"953_CR41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"key":"953_CR42","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/ALN.0b013e3181b437b1","volume":"111","author":"M Sigtermans","year":"2009","unstructured":"Sigtermans M, Dahan A, Mooren R, et al. S (+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology. 2009;111:892\u2013903.","journal-title":"Anesthesiology"},{"key":"953_CR43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/ALN.0000000000001798","volume":"127","author":"K Jonkman","year":"2017","unstructured":"Jonkman K, Duma A, Olofsen E, et al. Pharmacokinetics and bioavailability of inhaled esketamine in healthy volunteers. Anesthesiology. 2017;127:675\u201383.","journal-title":"Anesthesiology"},{"key":"953_CR44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/psp4.12346","volume":"7","author":"MW Ashraf","year":"2018","unstructured":"Ashraf MW, Peltoniemi MA, Olkkola KT, et al. Semimechanistic population pharmacokinetic model to predict the drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers. CPT Pharmacomet Syst Pharmacol. 2018;7:687\u201397.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"953_CR45","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00000542-199212000-00022","volume":"77","author":"ED Kharasch","year":"1992","unstructured":"Kharasch ED, Labroo R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology. 1992;77:1201\u20137.","journal-title":"Anesthesiology"},{"key":"953_CR46","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1995.","edition":"3"},{"key":"953_CR47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","volume":"71","author":"S Fanta","year":"2015","unstructured":"Fanta S, Kinnunen M, Backman JT, et al. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"953_CR48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 \u201cpie\u201d. Drug Metab Dispos. 2006;34:880\u20136.","journal-title":"Drug Metab Dispos"},{"key":"953_CR49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","volume":"26","author":"S T\u00fcrker","year":"2004","unstructured":"T\u00fcrker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004;26:137\u201342.","journal-title":"Pharm World Sci"},{"key":"953_CR50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12:288\u2013311.","journal-title":"J Pharm Pharm Sci"},{"key":"953_CR51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdd.336","volume":"24","author":"Y Yanagihara","year":"2003","unstructured":"Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24:37\u201343.","journal-title":"Biopharm Drug Dispos"},{"key":"953_CR52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s002280100353","volume":"57","author":"J Persson","year":"2002","unstructured":"Persson J, Hasselstr\u00f6m J, Maurset A, et al. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol. 2002;57:869\u201375.","journal-title":"Eur J Clin Pharmacol"},{"key":"953_CR53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejpain.2010.06.016","volume":"15","author":"A Dahan","year":"2011","unstructured":"Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain. 2011;15:258\u201367.","journal-title":"Eur J Pain"},{"key":"953_CR54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI101676","volume":"24","author":"SE Bradley","year":"1945","unstructured":"Bradley SE, Ingelfinger FJ, Bradley GP, et al. The estimation of hepatic blood flow in man. J Clin Investig. 1945;24:890\u20137.","journal-title":"J Clin Investig"},{"key":"953_CR55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1460-9592.2011.03548.x","volume":"21","author":"KE Brunette","year":"2011","unstructured":"Brunette KE, Anderson BJ, Thomas J, et al. Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. Paediatr Anaesth. 2011;21:653\u201362.","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"953_CR56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01059688","volume":"5","author":"KS Pang","year":"1977","unstructured":"Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a \u201cwell-stirred\u201d model and a \u201cparallel tube\u201d model: influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625\u201353.","journal-title":"J Pharmacokinet Biopharm"},{"key":"953_CR57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"953_CR58","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","volume":"30","author":"Y Hijazi","year":"2002","unstructured":"Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853\u20138.","journal-title":"Drug Metab Dispos"},{"key":"953_CR59","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","volume":"50","author":"M Man","year":"2010","unstructured":"Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50:929\u201340.","journal-title":"J Clin Pharmacol"},{"key":"953_CR60","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","volume":"7","author":"P Arora","year":"2002","unstructured":"Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967\u201375.","journal-title":"Drug Discov Today"},{"key":"953_CR61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003088-198815050-00002","volume":"15","author":"KW Woodhouse","year":"1988","unstructured":"Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet. 1988;15:287\u201394.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00953-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00953-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00953-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:30:18Z","timestamp":1628602218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00953-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00953-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"6 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical studies were supported by research funding from Janssen Research and Development, and the analyses presented here were supported by Janssen Research and Development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stefaan Rossenu, Peter Zannikos, Partha Nandy, Jaskaran Singh, Wayne Drevets, and Juan Jose Perez Ruixo were employees and shareholders of Janssen Pharmaceutical Companies at the time this analysis was conducted. Carlos P\u00e9rez-Ruixo was an employee of Janssen Pharmaceutical Companies at the time this analysis was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/Competing interests"}},{"value":"All studies were conducted in accordance with principles for human experimentation as defined in the 1964 Declaration of Helsinki and were approved by the human investigational review board of each study center and by the competent authority of each country.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each subject before enrollment in the studies after being advised of the potential risks and benefits of the study, as well as the investigational nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors revised the article for important intellectual content and provided final approval of the published version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study belong to Janssen Research & Development and are not publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Carlos Perez Ruixo performed the population pharmacokinetic analysis, executed the model-based simulations, and took the lead in writing the manuscript. Stefaan Rossenu, Peter Zannikos, Partha Nandy, Jaskaran Singh, Wayne Drevets, and Juan Jose Perez Ruixo substantially contributed to the design of the clinical studies that were included in the analyses, reviewed early versions of the manuscript, contributed to the scientific content (including data analysis and interpretation of the results), and provided approval of the final version that was submitted for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}